Encompass Health (NYSE:EHC) Price Target Raised to $129.00 at Barclays

Encompass Health (NYSE:EHC - Get Free Report) had its target price increased by stock analysts at Barclays from $118.00 to $129.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has an "overweight" rating on the stock. Barclays's price objective would suggest a potential upside of 11.83% from the stock's current price.

Other equities analysts have also issued reports about the stock. StockNews.com lowered shares of Encompass Health from a "buy" rating to a "hold" rating in a research report on Wednesday, April 16th. William Blair reaffirmed an "outperform" rating on shares of Encompass Health in a research report on Friday, February 7th. KeyCorp raised their price target on shares of Encompass Health from $117.00 to $120.00 and gave the stock an "overweight" rating in a research report on Monday, February 10th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $110.00 price target on shares of Encompass Health in a research report on Tuesday, February 11th. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $120.86.

Encompass Health Stock Performance

Shares of NYSE EHC traded up $1.98 during mid-day trading on Friday, reaching $115.35. 1,228,258 shares of the company were exchanged, compared to its average volume of 677,913. The company's 50-day simple moving average is $100.35 and its 200-day simple moving average is $98.71. The company has a quick ratio of 1.04, a current ratio of 1.05 and a debt-to-equity ratio of 0.84. The stock has a market capitalization of $11.62 billion, a P/E ratio of 25.86, a P/E/G ratio of 2.31 and a beta of 0.87. Encompass Health has a twelve month low of $82.38 and a twelve month high of $115.83.

Encompass Health (NYSE:EHC - Get Free Report) last posted its earnings results on Thursday, April 24th. The company reported $1.37 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.19 by $0.18. The company had revenue of $1.46 billion during the quarter, compared to analysts' expectations of $1.43 billion. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. Encompass Health's quarterly revenue was up 10.6% compared to the same quarter last year. During the same quarter last year, the company posted $1.12 EPS. As a group, research analysts predict that Encompass Health will post 4.8 earnings per share for the current year.

Insider Activity at Encompass Health

In other news, CAO Andrew L. Price sold 5,042 shares of the firm's stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $98.29, for a total value of $495,578.18. Following the completion of the sale, the chief accounting officer now directly owns 69,164 shares in the company, valued at $6,798,129.56. This trade represents a 6.79 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 2.10% of the stock is currently owned by company insiders.

Institutional Trading of Encompass Health

Several large investors have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. lifted its position in Encompass Health by 0.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 644,764 shares of the company's stock valued at $59,544,000 after acquiring an additional 4,345 shares in the last quarter. Central Pacific Bank Trust Division lifted its position in Encompass Health by 15.1% in the 4th quarter. Central Pacific Bank Trust Division now owns 3,195 shares of the company's stock valued at $295,000 after acquiring an additional 418 shares in the last quarter. Merit Financial Group LLC bought a new position in shares of Encompass Health during the 4th quarter worth approximately $374,000. MassMutual Private Wealth & Trust FSB lifted its position in shares of Encompass Health by 87.8% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company's stock worth $27,000 after buying an additional 137 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S purchased a new position in Encompass Health in the fourth quarter valued at approximately $4,160,000. 97.25% of the stock is currently owned by institutional investors and hedge funds.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.